SCHEMBL8203230

SCHEMBL8203230

NCc1ccc(CN[C@H](C(=O)OC2CCCC2)c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
TPSAB1 Q15661 2/20 0.48
TPSD1 Q9BZJ3 2/20 0.48
TPSG1 Q9NRR2 2/20 0.48
MMP2 P08253 2/20 0.47
MMP9 P14780 2/20 0.47
ANPEP P15144 2/20 0.47
LTA4H P09960 1/20 0.47
LAP3 P28838 1/20 0.47
NPEPPS P55786 1/20 0.47
ERAP2 Q6P179 1/20 0.47
ERAP1 Q9NZ08 1/20 0.47
MAPK14 Q16539 2/20 0.44
BDKRB2 P30411 1/20 0.43
F2 P00734 3/20 0.42
PRSS1 P07477 2/20 0.42
F10 P00742 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC1 Q13547 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27784577 1.00 MEN1 (0.50) MEN1KMT2ATPSAB1TPSD1TPSG1
SCHEMBL1491678 0.84 EPHX1 (0.46) MEN1KMT2AMMP2MMP9ANPEP
SCHEMBL1491681 0.84 EPHX1 (0.46) MEN1KMT2AMMP2MMP9ANPEP
SCHEMBL1491449 0.82 KLKB1 (0.49) TPSAB1TPSD1TPSG1F2PRSS1
SCHEMBL1491446 0.82 KLKB1 (0.49) TPSAB1TPSD1TPSG1F2PRSS1
SCHEMBL2279040 0.81 MEN1 (0.54) MEN1KMT2AMMP2MMP9ANPEP
SCHEMBL19236566 0.81 SMN1; SMN2 (0.47) MEN1KMT2AMMP2MMP9ANPEP
SCHEMBL1491603 0.79 MEN1 (0.55) MEN1KMT2AMMP2MMP9ANPEP
SCHEMBL1491605 0.79 MEN1 (0.55) MEN1KMT2AMMP2MMP9ANPEP
SCHEMBL1491510 0.79 MEN1 (0.48) MEN1KMT2ATPSAB1TPSD1TPSG1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8962825-B2 Hydroxamates as inhibitors of histone deacetylase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-02-24 US disclosed
US-8962825-B2 Hydroxamates as inhibitors of histone deacetylase GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2015-02-24 US disclosed
EP-2077999-B1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD (GB) 2014-07-30 EP disclosed
CN-101553475-B Hydroxamic acids as inhibitors of histone deacetylase CHROMA THERAPEUTICS LTD 2013-04-24 CN disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2010-12-16 US disclosed
CN-101553475-A Hydroxamic acids as inhibitors of histone deacetylase CHROMA THERAPEUTICS LTD (GB) 2009-10-07 CN disclosed
WO-2008053131-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE CHROMA THERAPEUTICS LTD. (GB) 2008-05-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317678-A1 HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE H1-2, HDAC1, H1-0 MEN1 1608/4885KMT2A 92/4885TPSAB1 1248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.